A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
- Author
- J Reekie, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fätkenheuer, JD Lundgren, A Mocroft, the EuroSIDA study group and Linos Vandekerckhove (UGent)
- Organization
- Abstract
- Objectives : The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because of toxicity or treatment failure, development of clinical disease or serious long-term adverse events. The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures. Methods : Patients starting a nevirapine, efavirenz or lopinavir-based cART regimen for the first time after 1 January 2000 were included in the analysis. Follow-up started >= 3 months after initiation of treatment if viral load was < 500 HIV-1 RNA copies/mL. Durability was measured as discontinuation rate or development/worsening of clinical markers. Results : A total of 603 patients (21%) started nevirapine-based cART, 1465 (51%) efavirenz, and 818 (28%) lopinavir. After adjustment there was no significant difference in the risk of discontinuation for any reason between the groups on nevirapine and efavirenz (P=0.43) or lopinavir (P=0.13). Compared with the nevirapine group, those on efavirenz had a 48% (P=0.0002) and those on lopinavir a 63% (P < 0.0001) lower risk of discontinuation because of treatment failure and a 31% (P=0.01) and 66% (P <.0001) higher risk, respectively, of discontinuation because of toxicities or patient/physician choice. There were no significant differences in the incidence of non-AIDS-related events, worsening anaemia, severe weight loss, increased aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels or increased total cholesterol. Compared with patients on nevirapine, those on lopinavir had an 80% higher incidence of high-density lipoprotein (HDL) cholesterol decreasing below 0.9 mmol/L (P=0.003), but there was no significant difference in this variable between those on nevirapine and those on efavirenz (P=0.39). Conclusions : The long-term durability of nevirapine-based cART, based on risk of all-cause discontinuation and development of long-term adverse events, was comparable to that of efavirenz or lopinavir, in patients in routine clinical practice across Europe who initially tolerated and virologically responded to their regimen.
- Keywords
- antiviral therapy, long-term adverse events, durability, HIV-INFECTED PATIENTS, RETROVIRAL-NAIVE PATIENTS, ANTIRETROVIRAL THERAPY, INITIAL TREATMENT, REGIMENS, COHORT, LAMIVUDINE, ADULTS, ASSOCIATION, COMBINATION
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 220.75 KB
-
(...).doc
- full text
- |
- UGent only
- |
- application/msword
- |
- 51.71 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-3226576
- MLA
- Reekie, J., et al. “A Comparison of the Long-Term Durability of Nevirapine, Efavirenz and Lopinavir in Routine Clinical Practice in Europe: A EuroSIDA Study.” HIV MEDICINE, vol. 12, no. 5, 2011, pp. 259–68, doi:10.1111/j.1468-1293.2010.00877.x.
- APA
- Reekie, J., Reiss, P., Ledergerber, B., Sedlacek, D., Parczewski, M., Gatell, J., … Vandekerckhove, L. (2011). A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV MEDICINE, 12(5), 259–268. https://doi.org/10.1111/j.1468-1293.2010.00877.x
- Chicago author-date
- Reekie, J, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, et al. 2011. “A Comparison of the Long-Term Durability of Nevirapine, Efavirenz and Lopinavir in Routine Clinical Practice in Europe: A EuroSIDA Study.” HIV MEDICINE 12 (5): 259–68. https://doi.org/10.1111/j.1468-1293.2010.00877.x.
- Chicago author-date (all authors)
- Reekie, J, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fätkenheuer, JD Lundgren, A Mocroft, the EuroSIDA study group, and Linos Vandekerckhove. 2011. “A Comparison of the Long-Term Durability of Nevirapine, Efavirenz and Lopinavir in Routine Clinical Practice in Europe: A EuroSIDA Study.” HIV MEDICINE 12 (5): 259–268. doi:10.1111/j.1468-1293.2010.00877.x.
- Vancouver
- 1.Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, et al. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV MEDICINE. 2011;12(5):259–68.
- IEEE
- [1]J. Reekie et al., “A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study,” HIV MEDICINE, vol. 12, no. 5, pp. 259–268, 2011.
@article{3226576, abstract = {{Objectives : The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because of toxicity or treatment failure, development of clinical disease or serious long-term adverse events. The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures. Methods : Patients starting a nevirapine, efavirenz or lopinavir-based cART regimen for the first time after 1 January 2000 were included in the analysis. Follow-up started >= 3 months after initiation of treatment if viral load was < 500 HIV-1 RNA copies/mL. Durability was measured as discontinuation rate or development/worsening of clinical markers. Results : A total of 603 patients (21%) started nevirapine-based cART, 1465 (51%) efavirenz, and 818 (28%) lopinavir. After adjustment there was no significant difference in the risk of discontinuation for any reason between the groups on nevirapine and efavirenz (P=0.43) or lopinavir (P=0.13). Compared with the nevirapine group, those on efavirenz had a 48% (P=0.0002) and those on lopinavir a 63% (P < 0.0001) lower risk of discontinuation because of treatment failure and a 31% (P=0.01) and 66% (P <.0001) higher risk, respectively, of discontinuation because of toxicities or patient/physician choice. There were no significant differences in the incidence of non-AIDS-related events, worsening anaemia, severe weight loss, increased aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels or increased total cholesterol. Compared with patients on nevirapine, those on lopinavir had an 80% higher incidence of high-density lipoprotein (HDL) cholesterol decreasing below 0.9 mmol/L (P=0.003), but there was no significant difference in this variable between those on nevirapine and those on efavirenz (P=0.39). Conclusions : The long-term durability of nevirapine-based cART, based on risk of all-cause discontinuation and development of long-term adverse events, was comparable to that of efavirenz or lopinavir, in patients in routine clinical practice across Europe who initially tolerated and virologically responded to their regimen.}}, author = {{Reekie, J and Reiss, P and Ledergerber, B and Sedlacek, D and Parczewski, M and Gatell, J and Katlama, C and Fätkenheuer, G and Lundgren, JD and Mocroft, A and EuroSIDA study group, the and Vandekerckhove, Linos}}, issn = {{1464-2662}}, journal = {{HIV MEDICINE}}, keywords = {{antiviral therapy,long-term adverse events,durability,HIV-INFECTED PATIENTS,RETROVIRAL-NAIVE PATIENTS,ANTIRETROVIRAL THERAPY,INITIAL TREATMENT,REGIMENS,COHORT,LAMIVUDINE,ADULTS,ASSOCIATION,COMBINATION}}, language = {{eng}}, number = {{5}}, pages = {{259--268}}, title = {{A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study}}, url = {{http://doi.org/10.1111/j.1468-1293.2010.00877.x}}, volume = {{12}}, year = {{2011}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: